DOCSLIB.ORG

Author (Ref) N High Quality Intervention Indication Ooutcome Gastroenterology Alam (2) 55 No Trimethoprim-Sulphamethoxazole Diar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author (Ref) N High Quality Intervention Indication Ooutcome Gastroenterology Alam (2) 55 No Trimethoprim-Sulphamethoxazole Diar High Author (ref) N Quality Intervention Indication oOutcome Gastroenterology Alam (2) 55 No Trimethoprim-sulphamethoxazole Diarrhoea Duration of diarrhoea Battaglia (7) 325 No Otilonium bromide Irritable bowel syndrome Global assessment, other Cezard (18) 67 No Racecadotril Diarrhoea Duration of diarrhoea Gade (38) 54 Yes Paraghurt® Irritable bowel syndrome Global assessment, physician Hovdenak (46) 12 No Loperamide Irritable bowel syndrome Global assessment, patient Kaplan (53) 256 Yes Loperamide Diarrhoea Duration of diarrhoea Maria (57) 27 No Botulinum toxin Anal fissure Global assessment, physician Milo (64) 66 No Domperidone Irritable bowel syndrome Global assessment, other Nayak (69) 30 No Metronidazole 2g Irritable bowel syndrome Pain Rossignol (82) 89 No Nitazoxanide Intestinal infection Global assessment, other Sand (86) 25 No Nifedipine Gallbladder stones Pain Skoubo-Kirstensen (93) 58 No Sucralfate Gastritis Global assessment, patient Gynecology & obstetrics Bettigole (12) 33 No Fenoprofen Childbirth Pain Demory (27) 48 No Pyrrolidone carboxylate of magnesium Childbirth Dystocia Di Carlo (28) 28 No Leuprolide acetate + tibolone Premenstrual syndrome Depression Eriksson (33) 44 No Paroxetin Premenstrual syndrome Global assessment, patient Fleming (35) 92 No Metformin Oligomenorrhoea Global assessment, physician Grio (41) 88 No Tamoxifen Premenstrual syndrome Global assessment, other Hopkinson (44) 141 No Ibuprofen Childbirth Pain Humphrey (49) 89 Yes Sulindac Childbirth Occurrence of preterm labour Louviere (56) 450 No Deladumone OB Breastfeeding Pain McCaul (58) 84 No Ampicillin Childbirth Time to delivery Mendes (63) 19 No Metoclopramide Amenorrhoea Global assessment, physician Stein (95) 70 No Itraconazole Vaginal candidiasis Global assessment, physician Von Holst (106) 173 No Estradiol Postmenopausal complaints Flushes Warren (107) 50 No Sequential antibiotics Cystitis Global assessment, patient 0.00001 0.0001 0.001 0.01 0.1 1 10 100 Note that an earlier version of this table (Study_characteristics_of_allopathy_studies.pdf ) posted on our website on Dec 17, 2005 was incorrect due to errors occurring during the production of the graphs. The current version was posted on our website on Dec 23, 2005. High Author (ref) N Quality Intervention Indication Outcome Musculoscelettal complaints Barlas (6) 24 No Aspirin Physical activity Pain Giner (39) 103 No Emla® Arterial cannulation Pain Grossman (42) 20 No Ibuprofen Physical activity Soreness Lacey (54) 1282 No Piroxicam Soft tissue injury Global assessment, physician McLatchie (59) 67 No Ibuprofen Ankle sprains Global assessment, physician Memeo (61) 100 No Flurbiprofen Soft tissue injury Global assessment, patient Paddon-Jones (74) 17 No Beta-hydroxy-beta-methylbutyrate Muscle damage Soreness Ramesh (78) 80 No Ibuprofen Injuries Global assessment, patient Semark (91) 25 No Flurbiprofen Physical activity Soreness Thompson (101) 16 No Vitamin C Physical activity Soreness Weller (108) 20 No Magnesium Physical activity Global assessment, patient Neurology Attias (4) 38 No Scopolamine Seasickness Global assessment, patient Diamond (29) 63 No Butorphanol Migraine Global assessment, patient Goldstein (40) 80 No Lanepitant Migraine Migraine attacks Horn (45) 454 Yes Nimodipine Stroke Occurrence of poor outcome Huber (47) 50 No Piracetam Aphasia Global assessment, physician Narotam (68) 20 No CP-0127 Brain injury Global assessment, physician Sacco (84) 1367 No Gavestinel Stroke Death Schmitt (89) 57 No Botulinum toxin A Headache Pain Shupak (92) 66 No Cinnarizine Seasickness Global assessment, patient Storey (97) 40 No Topiramate Migraine Frequency of attacks 0.00001 0.0001 0.001 0.01 0.1 1 10 100 High Author (ref) N Quality Intervention Indication Outcome Pollinosis and asthma Althaus (3) 127 No N-acetyl-aspartyl glutamic acid Pollinosis Ocular symptoms Bergmann (10) 123 No Beclomethasone dipropionate Asthma FEV1 Bodtger (16) 34 No Immunotherapy Pollinosis Global assessment, patient Boos (14) 131 No Nedocromil sodium Asthma FEV1 Brunet (17) 27 No Immunotherapy Pollinosis Global assessment, patient Ciprandi (20) 20 No Acetylsalicylic acid Pollinosis Global assessment, physician Ciprandi (19) 39 No Cromoglycate + chlorphenamine Pollinosis Global assessment, other Davis (24) 57 No Levocabastine Conjunctivitis Global assessment, physician Huerta Lopez (48) 60 No Ketotifen Asthma Global assessment, physician Munk (67) 140 No Triamcinolone acetonide Allergic rhinitis Global assessment, patient Möller (66) 146 Yes Nedocromil sodium Pollinosis Global assessment, other Reid (79) 66 No Sodium cromoglycate Asthma PEFR Stelmach (96) 32 No Nedocromil sodium Asthma Global assessment, other Taudorf (100) 37 No Immunotherapy Pollinosis Ocular symptoms Wüthrich (109) 35 No Disodium cromoglycate Pollinosis Global assessment, patient de Molina (26) 65 No Ebastine Rhinitis Global assessment, patient Respiratory tract infections Belshe (8) 1358 No Influenza vaccine Influenza Occurrence of influenza Bertin (11) 146 No Ibuprofen Otitis media Pain Cohen (21) 19 No Ribavirin Influenza Occurrence of influenza Crawford (22) 56 No Rimantadine Influenza Occurrence of influenza like disease De Flora (25) 248 Yes N-acetylcysteine Influenza like disease Occurrence of influenza like disease Dolin (30) 265 No Rimantadine Influenza Occurrence of influenza like disease Frachet (36) 90 No Tiaprofenic acid Sinusitis Global assessment, patient Hutton (50) 54 No Dimetapp® Common cold Global assessment, other Kaiser (52) 285 No Zanamivir Influenza Occurrence of influenza like disease Morrone (65) 17 No Moguisteine Cough Global assessment, patient Nelson (71) 34 No Penicillin Pharyngitis Global assessment, other Nicholson (72) 319 Yes Oseltamivir Influenza Global assessment, other Peters (76) 548 No Oseltamivir Influenza Occurrence of influenza Reuman (80) 316 Yes Amantadine hydrochloride Influenza Occurrence of influenza Rodriguez (81) 74 No Immune globuline Respiratory tract infection Global assessment, physician Ruohola (83) 208 No Fluticasone propionate Otitis media Occurrence of acute otitis media Schlenter (88) 262 No Broncho-Vaxom® Sinusitis Headache Sclafani (90) 164 No Amoxicillin/clavulanate potassium Adenotonsillar hypertrophy Global assessment, physician Treanor (102) 253 No Oseltamivir Influenza Temperature Van Eygen (103) 70 No Levamisole Respiratory tract infection Occurrence of symptoms Van Voris (104) 31 No Rimantadine hydrochloride Influenza Global assessment, other 0.00001 0.0001 0.001 0.01 0.1 1 10 100 High Author (ref) N Quality Intervention Indication Outcome Surgery & anesthesiology Benson (9) 23 No Cisapride Postoperative ileus Time to first wind Boghaert (13) 53 No Cisapride Postoperative Ileus Occurrence of first wind Crowley (23) 273 Yes Metronidazole Postoperative infection Occurrence of postoperative infection Hoernecke (43) 80 No Wobenzyme® Hand surgery Pain Ilkjaer (51) 50 No Dextromethorphan Hysterectomy Pain Mehnert (60) 100 No Indomethacin Tooth extraction Pain Mendel (62) 34 No Alfentanil Postoperative agitation Agitation Negro (70) 30 No 2alpha-thenoylthiopropionylglycine Postoperative lung complications Occurrence of complications Oertli (73) 153 No Tranexamic acid Surgery Occurrence of haematomas Sadek (85) 89 No Ceruletide Postoperative ileus Time to first wind Schäffer (87) 34 No Nalbuphine Surgery Pain Taguchi (99) 52 No ADL8-2698 Postoperative ileus Occurrence of first wind Miscellanous Adamietz (1) 38 No Povidone-iodine Mucositis Global assessment, other Bahadori (5) 17 No Chromium picolinate Obesity BMI Boureau (15) 38 No Paracetamol+ Codeine Rheumatoid Arthritis Global assessment, patient Dominguez (31) 57 No Hidrosmin Venous insufficiency Pain Enzi (32) 133 No Dexfenfluramine Obesity Body weight Eron (34) 257 No Interferon alpha-2b Condylomata acuminata Global assessment, physician Frattola (37) 37 No Alpidem Anxiety Anxiety Lievens (55) 83 No Sucralfate Radiotherapy Mucositis Patterson (75) 65 No Lorazepam Burns Pain Petrovic (77) 39 No Lormetazepam Benzodiazepine withdrawal Global assessment, other Smolen (94) 221 No Leflunomide Rheumatoid Arthritis Global assessment, physician Taddio (98) 60 No Lidocaine-prilocaine Injection Pain Vercoulen (105) 95 No Fluoxetine Chronic fatigue syndrome Global assessment, patient Yazar (110) 70 No Silver nitrate Warts Global assessment, other 0.00001 0.0001 0.001 0.01 0.1 1 10 100.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Rotenone-Induced Inner Retinal Degeneration Via Presynaptic
    www.nature.com/scientificreports OPEN Rotenone-induced inner retinal degeneration via presynaptic activation of voltage-dependent sodium and L-type calcium channels in rats Masaaki Sasaoka, Takashi Ota & Masaaki Kageyama* Rotenone, a mitochondrial complex I inhibitor, causes retinal degeneration via unknown mechanisms. To elucidate the molecular mechanisms of its action, we further characterized a rat model of rotenone- induced retinal degeneration. Intravitreal injection of rotenone (2 nmol/eye) damaged mainly the inner retinal layers, including cell loss in the ganglion cell and inner nuclear layers, which were very similar to those induced by 10 nmol/eye N-methyl-D-aspartate (NMDA). These morphological changes were accompanied by the reduced b-wave amplitude of electroretinogram, and increased immunostaining of 2,4-dinitrophenyl, an oxidative stress marker. Rotenone also downregulated expression of neuroflament light-chain gene (Nf) as a retinal ganglion cell (RGC) marker. This efect was prevented by simultaneous injection of rotenone with antioxidants or NMDA receptor antagonists. More importantly, voltage-dependent sodium and L-type calcium channel blockers and intracellular calcium signaling modulators remarkably suppressed rotenone-induced Nf downregulation, whereas none of these agents modifed NMDA-induced Nf downregulation. These results suggest that rotenone-induced inner retinal degeneration stems from indirect postsynaptic NMDA stimulation that is triggered by oxidative stress-mediated presynaptic intracellular calcium signaling via activation of voltage-dependent sodium and L-type calcium channels. Rotenone is a naturally occurring and broad-spectrum pesticide that inhibits the activity of NADH dehydroge- nase in the mitochondrial respiratory chain complex I1. Because of this unique biological activity, rotenone has been used as a versatile tool to study involvement of mitochondrial functions and oxidative stress in neuronal cell death.
    [Show full text]
  • A Radical Approach to Stroke Therapy
    Commentary A radical approach to stroke therapy James McCulloch* and Deborah Dewar Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, Glasgow G61 1QH, United Kingdom troke is a major cause of death and readily crosses the blood–brain barrier, (mitogen-activated protein kinases͞ Sdisability throughout the developed to augment endogenous brain ascorbic ERK1͞2). During ischemia, ERK1͞2 are world. Cerebrovascular disease ranks acid levels by up to 2 mM. However, in dephosphorylated, and there is a signif- third after cancer and heart disease as a the brain, ascorbic acid levels are heter- icant increase in ERK1͞2 phosphoryla- cause of death in the European Union ogeneous and highly compartmental- tion during reperfusion after forebrain and the U.S. The economic and social ized. In the rat, normal neuronal, glial, ischemia. Neurons and oligodendrocytes burdens of stroke are not consequences and cerebrospinal fluid levels of ascorbic at the margin of a focal ischemic lesion of mortality; they are imposed by the acid are Ϸ10 mM, 1 mM, and 0.5 mM, display increased MEK1͞2, indicating large majority of stroke patients who respectively (3). The antioxidant effects that this signaling pathway is activated survive but are physically and mentally of ascorbic acid at all of these sites within after ischemia and reperfusion in vivo disabled by stroke-induced brain dam- the brain could contribute to the efficacy (8). If MEK1͞2 is inhibited by the novel age. In the U.S., less than 2% of stroke of this agent in ischemia. Brain ascorbic agent, U0126, the extent of brain damage patients benefit from access to early acid levels are highly dynamic (although is reduced after either forebrain or focal thrombolysis, which removes the primary under rigorous homeostatic control), ischemia (2).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • ACCP Guideline: Diagnosis and Management of Cough
    Diagnosis and Management of Cough Executive Summary ACCP Evidence-Based Clinical Practice Guidelines Richard S. Irwin, MD, FCCP, Chair; Michael H. Baumann, MD, FCCP (HSP Liaison); Donald C. Bolser, PhD; Louis-Philippe Boulet, MD, FCCP (CTS Representative); Sidney S. Braman, MD, FCCP; Christopher E. Brightling, MBBS, FCCP; Kevin K. Brown, MD, FCCP; Brendan J. Canning, PhD; Anne B. Chang, MBBS, PhD; Peter V. Dicpinigaitis, MD, FCCP; Ron Eccles, DSc; W. Brendle Glomb, MD, FCCP; Larry B. Goldstein, MD; LeRoy M. Graham, MD, FCCP; Frederick E. Hargreave, MD; Paul A. Kvale, MD, FCCP; Sandra Zelman Lewis, PhD; F. Dennis McCool, MD, FCCP; Douglas C. McCrory, MD, MHSc; Udaya B.S. Prakash, MD, FCCP; Melvin R. Pratter, MD, FCCP; Mark J. Rosen, MD, FCCP; Edward Schulman, MD, FCCP (ATS Representative); John Jay Shannon, MD, FCCP (ACP Representative); Carol Smith Hammond, PhD; and Susan M. Tarlo, MBBS, FCCP (CHEST 2006; 129:1S–23S) Abbreviations: ACE ϭ angiotensin-converting enzyme; ACP ϭ American College of Physicians; A/D ϭ antihistamine/ decongestant; ATS ϭ American Thoracic Society; BPC ϭ bronchoprovocation challenge; CTS ϭ Canadian Thoracic Society; DPB ϭ diffuse panbronchiolitis; dTap ϭ acellular pertussis; FEES ϭ fiberoptic endoscopic evaluation of swallowing; GERD ϭ gastroesophageal reflux disease; HRCT ϭ high-resolution CT; HSP ϭ Health & Psychosocial Instruments; IBD ϭ inflammatory bowel disease; ICS ϭ inhaled corticosteroid; ILD ϭ interstitial lung disease; NAEB ϭ nonasthmatic eosinophilic bronchitis; NSCLC ϭ non-small cell lung cancer; SLP ϭ speech-language pathol- ogist; TB ϭ tuberculosis; UACS ϭ upper airway cough syndrome; URI ϭ upper respiratory infection; VC ϭ voluntary cough; VSE ϭ videofluoroscopic swallow evaluation ecognition of the importance of cough in clinical (3) updates and expands, when appropriate, all pre- R medicine was the impetus for the original evi- vious sections; and (4) adds new sections with topics dence-based consensus panel report on “Managing that were not previously covered.
    [Show full text]
  • Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2014 Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance Da Zhang Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Other Pharmacy and Pharmaceutical Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/3533 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ©Da Zhang, 2014 All Rights Reserve EVALUATION OF THE ALLOMETRIC EXPONENTS IN PREDICTION OF HUMAN DRUG CLEARANCE A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By Da Zhang Master of Science, University of Arizona, 2004 Director: F. Douglas Boudinot, Ph.D. Professor, School of Pharmacy, VCU Virginia Commonwealth University Richmond, Virginia August, 2014 ACKNOWLEDGEMENTS First and foremost, I would like to sincerely thank my advisor, Dr. F. Douglas Boudinot, for giving me the opportunity to pursue graduate studies under his guidance and for his continuous professional support, guidance, encouragement and patience throughout my graduate program. He was always delighted in sharing his vast knowledge and kind warmth. I would also like to thank Dr. Ahmad for his scientific advice and support through the complet ion of my degree. He has been a kind and helpful mentor for me. I would like to acknowledge my graduate committee members, Drs.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Cardiac Glycosides Provide Neuroprotection Against Ischemic Stroke: Discovery by a Brain Slice-Based Compound Screening Platform
    Cardiac glycosides provide neuroprotection against ischemic stroke: Discovery by a brain slice-based compound screening platform James K. T. Wang*†, Stuart Portbury*‡, Mary Beth Thomas*§, Shawn Barney*, Daniel J. Ricca*, Dexter L. Morris*¶, David S. Warnerʈ, and Donald C. Lo*,**†† *Cogent Neuroscience, Inc., Durham, NC 27704; ʈMultidisciplinary Neuroprotection Laboratories and Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710; and **Center for Drug Discovery and Department of Neurobiology, Duke University Medical Center, Durham, NC 27704 Edited by Charles F. Stevens, The Salk Institute for Biological Studies, La Jolla, CA, and approved May 17, 2006 (received for review February 3, 2006) We report here the results of a chemical genetic screen using small intrinsically problematic for a number of reasons, including inher- molecules with known pharmacologies coupled with a cortical ent limitations on therapeutic time window and clinically limiting brain slice-based model for ischemic stroke. We identified a small- side-effect profiles. Consequently, much attention has been focused molecule compound not previously appreciated to have neuropro- in recent years on using genomic, proteomic, and other systems tective action in ischemic stroke, the cardiac glycoside neriifolin, biology approaches in identifying new drug target candidates for and demonstrated that its properties in the brain slice assay stroke drug intervention (see review in ref. 5). included delayed therapeutic potential exceeding 6 h. Neriifolin is In this context we developed a tissue-based, high-content assay structurally related to the digitalis class of cardiac glycosides, and model for ischemic stroke based on biolistic transfection of visual ؉ ؉ its putative target is the Na ͞K -ATPase.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Supplemental Material Liu Page 1
    Supplementary material Stroke Vasc Neurol Supplemental Material Liu Page 1 Supplemental Material Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Disorders Executive Summary and 2019 Update of Clinical Management of Ischemic Cerebrovascular Diseases Liu L, et al. Stroke Vasc Neurol 2020; 5:e000378. doi: 10.1136/svn-2020-000378 Supplementary material Stroke Vasc Neurol Supplemental Material Liu Page 2 Section 1 Definitions associated with ischemic cerebrovascular diseases. The definitions of ischemic cerebrovascular disease are shown in Table 1. Section 2 Emergency assessment and diagnosis of ischemic stroke patients Please refer to Figure 1 for details of the management process for ischemic stroke patients in the acute phase. I. First assessment of emergency (I) Medical history collection Acute ischemic stroke (AIS) patients suffer from acute onset. It is very important to inquire about the time of occurrence of symptoms, onset characteristics and progress, including symptom persistence, fluctuations and relief. If the disease starts onset during sleep, the time when the patient's last normal performance should be recorded. These patients may also get sick shortly before waking up, and the onset time is uncertain, but clinically the final normal time should still be calculated as the last normal time [1-2]. Using MRI to screen wake-up stroke patients who are not suitable for thrombectomy, intravenous thrombolysis helps patients get good prognosis [3]. Before the occurrence of current symptoms, some patients will have similar TIA symptoms that can be relieved automatically. The time window for thrombolytic therapy is calculated based on the occurrence time of current symptoms. The inquiry about whether there are causes related to haemorrhagic stroke before the occurrence of symptoms, such as emotional excitement, intense exercise, sudden change of body position, excessive blood pressure reduction, as well as whether there is a history of Liu L, et al.
    [Show full text]